CANADIAN PERSPECTIVE Series
The Evolving Role of PARP Inhibitors in Early Breast Cancer: A Canadian Perspective (west coast)
octobre 2025
Résumé
2 Live webinars tailored for healthcare professionals across Canada, featuring internationally renowned breast cancer expert Dr. Charles Geyer. Each session will be moderated by a leading Canadian oncologist from opposite coasts - Dr. Karen Gelmon (West Coast, Oct. 6th) and Dr. Stephanie Wong (East Coast, Oct. 7th) - to provide Canadian insights and perspectives.
This activity has been funded by an educational grant from AstraZeneca and is intended for healthcare practitioners only.
Points Saillants
- 1
Clinical considerations for germline BRCA (gBRCA) testing in early-stage breast cancer
- 2
Recent updates to the therapeutic landscape and emerging clinical challenges
- 3
Evidence supporting the integration of PARP inhibitors into treatment plans for patients with gBRCAm early TNBC and HR+/HER2- BC
- 4
Real-world patient case reviews exploring strategies for managing and supporting patients on PARP therapy
Charles E. Geyer Jr., MD, FACP
Commentaires (0)